<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35184935</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-0666</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical breast cancer</Title><ISOAbbreviation>Clin Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>The use of neoadjuvant therapy increases the rate of breast conservation in men with locally advanced breast cancer.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>358</EndPage><MedlinePgn>343-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2022.01.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1526-8209(22)00019-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Male breast cancer (MBC) is often diagnosed at a later stage and with a more unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast conservation (BCT). We sought to assess the practice patterns of neoadjuvant therapy (NT) in MBC patients and the impact on BCT.</AbstractText><AbstractText Label="METHODS">Men with nonmetastatic, invasive breast cancer were identified from the National Cancer Database. Patients were categorized as having small (cT1/2) or locally advanced (cT3/4) tumors and by whether they received NT (which included endocrine or chemotherapy). Univariate and multivariable analyses were performed to assess patterns of NT use and rates BCT.</AbstractText><AbstractText Label="RESULTS">Of 15,151 male patients, 4.8% received NT and 21.6% underwent BCT. NT was more common among males with cT3/4 tumors than those with cT1/2 tumors (8.2 vs. 2.1%, P &lt; .001). Overall, unadjusted rates of BCT were higher for patients receiving NT in the cT3/4 subgroup (19.0 vs. 12.5%, P &lt; .001), a difference which persisted on multivariable analysis. For all patients analyzed, overall survival (OS) did not differ between males who underwent NT and those who did not (110 vs. 122 months, P&#xa0;=&#xa0;.67), but NT was associated with poorer OS in both univariate and multivariate analyses for patients with cT3/4 tumors (both P &lt; .01).</AbstractText><AbstractText Label="CONCLUSIONS">Men with invasive breast cancer have an expected low rate of BCT, but NT appears to reduce the use of mastectomy in patients with locally advanced cancers. More work is needed to understand the impacts of BCT on locoregional recurrence and disease-free and overall survival for MBC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Austin D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Lankenau Medical Center, Wynnewood, PA. Electronic address: adwilliams5@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciocca</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabol</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carp</LastName><ForeName>Ned Z</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Breast Cancer</MedlineTA><NlmUniqueID>100898731</NlmUniqueID><ISSNLinking>1526-8209</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast conserving surgery</Keyword><Keyword MajorTopicYN="N">Male breast cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">Neoadjuvant endocrine therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>21</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35184935</ArticleId><ArticleId IdType="doi">10.1016/j.clbc.2022.01.004</ArticleId><ArticleId IdType="pii">S1526-8209(22)00019-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
